title: Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon?
authors.forename: Barbara
authors.initials: B
authors.lastname: McGovern
authors.forename: Ioana
authors.initials: I
authors.lastname: Bica
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications*; D018023:HIV Seronegativity; D006679:HIV Seropositivity; D006467:Hemophilia A / Q000150:complications*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons